

Minutes
Drug Utilization Review Board Meeting
DATE: 9/10/14



Meeting Purpose: Quarterly Open Board Meeting
Meeting opened at 6:00 PM by Chair, Patrick Reilly

Agenda Items:

- I. Welcome and Introductory Remarks
- II. DUR Clinical Update
- III. Synagis (palivizumab) Quality Assurance Analysis
- IV. Growth Hormone Quality Assurance Analysis
- V. MassHealth Drug List Update
- VI. DUR Operational Update
- VII. MassHealth Update

Agenda Item	Discussion	Conclusions/Follow Up
Review of Minutes	The June 11, 2014 Minutes were reviewed and accepted as written	Follow Up: N/A
Action	June Minutes approved as noted, new board member Timothy Fensky was introduced.	Conclusion: N/A

Agenda Item	Discussion	Conclusions/Follow Up
DUR Clinical Update	The Clinical research projects and outcomes were discussed.	Follow Up: Informational
Action	Discussed the following regarding the Clinical research projects: <ul style="list-style-type: none">• 60 New Drug Reviews in FY 14 including CNS agents, oncology agents, infectious disease and respiratory agents• There are 127 Drug Guidelines, and 106 have been updated this year, with 11 new guidelines• There were 51 Quality Assurance Analysis completed• Clinical proposals, clinical initiatives and residency projects make up the miscellaneous projects.• In total, 1,172 Clinical Cases were sent to Clinical review, with 746 cases, 174 under review, and 268 requiring outreach.	Conclusion: Informational

Agenda Item	Discussion	Conclusions/Follow Up
Synagis (palivizumab) Quality Assurance Analysis	An update of the Synagis Quality Assurance Analysis was provided.	Follow Up: Informational
Action	<ul style="list-style-type: none"> Respiratory syncytial virus (RSV) was discussed: <ul style="list-style-type: none"> Common in infants and children By 3 years old most children will have contracted RSV Outbreaks follow seasonal patterns May lead to more serious conditions such as pneumonia Synagis is used to treat RSV and prevent respiratory infection Dosing is 15 mg/kg monthly during RSV season <ul style="list-style-type: none"> Various recommendations are given depending on the diagnosis of infant Current PA requirements and approval criteria were discussed Utilization trends and PA data for most recent RSV season were discussed. Recommended to update the internal criteria based on the guidance given from the AAP 	Conclusion: Proceed with proposed changes as stated.

Agenda Item	Discussion	Conclusions/Follow Up
Growth Hormone Quality Assurance Analysis	Overview of the Growth Hormone QA	Follow Up: N/A
Action	<p>Background</p> <ul style="list-style-type: none"> Somatropin used to treat several pediatric and adult conditions GH products vary by dosing, administration and refrigeration requirements MassHealth requires a PA for all products in this class to prevent misuse and to ensure appropriate utilization <p>Discussion/Recommendations</p> <ul style="list-style-type: none"> From January 1, 2014 to June 30, 2014, there were a total of 149 utilizers with a total of 717 paid claims. The highest utilized agent was Norditropin® The agent with the highest average cost/claim was Humatrope® A total of 277 PA requests for 195 unique members Most of the sampled requests were for pediatric members and 	Conclusion: Proceed with proposed recommendations as stated.

	<p>submitted by endocrinologists</p> <ul style="list-style-type: none"> • Several unique topics were identified. • Recommendations for clarification of guidelines with regard to adult GHD/PHP. SGA with failed catch up growth, chronic renal failure, PWS and adherence. 	
--	---	--

Agenda Item	Discussion	Conclusions/Follow Up
MassHealth Drug List Update	Drug List Update	Follow Up: Informational
Action	<p>There will be 27 new drugs effective 10/27/14</p> <ul style="list-style-type: none"> • On 11/24/14 there will be new age limits for certain behavioral health medications and classes <ul style="list-style-type: none"> ○ Also, there will be PA for polypharmacy for members under 18 in these classes- Antianxiety, Antidepressants, Antipsychotics, Cerebral Stimulants, Mood Stabilizers ○ Fosrenol (lanthanum) will require PA ○ Pediatric Behavioral health medication PA form added • Updated Pharmacy initiatives- ADHD, Pain, Pediatric Behavioral Health Medication Initiative 	Conclusion: Informational

Agenda Item	Discussion	Conclusions/Follow Up
Operational Update	Quarterly Operational Update	Follow Up Informational
Action	<p>Provided MassHealth Operational Overview which includes the following:</p> <ul style="list-style-type: none"> • Both phone calls and prior authorization numbers average around 8,000 per month • The average wait time is under 20 seconds per month • The call abandoned rate is under 2% for the quarter • The Provider outreach has been rising due to new drugs and increased PA volume • Top 10 medications for which PA was requested: Abilify, buprenorphine/naloxone, atorvastatin, lidocaine, Lyrica, Suboxone, duloxetine, Advair,, montelukast, OxyContin 	Conclusion: Quarterly updates will continue to be provided as needed.
MassHealth Quarterly Update	<ul style="list-style-type: none"> • Massachusetts received federal approval to operate its own health insurance exchange. • The MassHealth departments are preparing for the change in elected officials, tying up loose ends and preparing reports to 	Conclusion: Quarterly updates will continue to be provided as needed.

	<p>present to the new governor when time occurs.</p> <ul style="list-style-type: none"> • Hepatitis C therapy caused a dramatic increase in state budget and projections for next year. • MassHealth is working on a pediatric behavioral health medication initiative. • There will be changes to the schedule for hydrocodone and will impact how MH process pharmacy claims for these products. 	
--	---	--

Attendance:

Members	Present
TRACEY APPLEBEE-COLE, R.PH.	
ADAM BARD BURROWS, M.D.	X
TIMOTHY FENSKY, R. PH.	X
LESLIE S. FISH, PHARM.D.	
KARIN GARDNER JOHNSON, M.D.	
CAMILLA S. GRAHAM, MD, MPH.	X
SARAH M. MCGEE, M.D.,	X
SOPHIE MCINTYRE, PHARM D.	X
AUDRA R. MEADOWS, MD, MPH.	X
BRIAN O'NEIL, R.PH.	
PATRICK REILLY, R.PH.	X
KAREN RYLE, M.S, R.PH.	X

Respectfully submitted by: Vincent Palumbo, Director of DUR

Date: _____